Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To determine the best oral anticoagulant/s for prevention of stroke in AF and for primary prevention, treatment and secondary prevention of thromboembolism (VTE). Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH): warfarin is the most frequently prescribed anticoagulant for treatment and secondary prevention of VTE. Warfarin-related bleeding is a major reason for hospitalisation for adverse drug effects. Warfarin is cheap but therapeutic monitoring increases treatment costs. Novel oral anticoagulants (NOACs) have more rapid onset and offset of action than warfarin, and more predictable dosing requirements.

Authors' conclusions
NOACs have advantages over warfarin in patients with AF, but we found no strong evidence that they should replace warfarin or LMWH in primary prevention, treatment or secondary prevention of VTE.

Project page URL
http://www.nets.nihr.ac.uk/projects/hta/119217

Final publication URL
https://www.journalslibrary.nihr.ac.uk/hta/hta21090/#/abstract

Indexing Status
Subject indexing assigned by CRD

MeSH
Anticoagulants; Atrial Fibrillations; Primary Prevention; Stroke; Secondary Prevention; Venous Thromboembolism

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
AccessionNumber
32013000946

Date abstract record published
16/12/2013